PALO ALTO, Calif., Nov. 11 /PRNewswire-FirstCall/ -- Telik, Inc. announced that company management will provide a corporate update at the CSFB Annual Healthcare Conference in Phoenix, Arizona on November 16, 2005 at 11:30 am Eastern time. A live webcast of the presentation will be available via the Telik website, www.telik.com, and an archived replay of the webcast will be available on the Telik website through November 23, 2005.
Telik, Inc. of Palo Alto, CA is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company’s most advanced drug development candidate is TELCYTA(TM) (TLK286), a tumor-activated small molecule product candidate. TELCYTA is in three Phase 3 registration trials in advanced ovarian and non- small cell lung cancer. A second drug development candidate, TELINTRA(TM) (TLK199), is in Phase 2 clinical development in myelodysplastic syndrome. Telik’s product candidates were discovered using its proprietary drug discovery technology, TRAP, which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at www.telik.com.
Telik, Inc.
CONTACT: Carol D. DeGuzman, Senior Director, Corporate Communications ofTelik, Inc., +1-650-845-7728, or cdeguzman@telik.com
Web site: http://www.telik.com/
